Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bon Natural Life ( (BON) ) has provided an update.
On May 12, 2025, Bon Natural Life Limited’s subsidiary, Xi’an App-Chem Bio (Tech) Co., Ltd, entered into a Sales Cooperation Agreement with Shanghai Risesun International Trade Co., Ltd. This agreement grants Shanghai Risesun the non-exclusive right to market and distribute BON’s tea pigment series products in China over a 24-month period, with a guaranteed sales value of at least $24 million. This strategic partnership aims to leverage the growing demand for tea pigment products in the digestive wellness and blood glucose regulation sectors, potentially positioning BON as a leader in this category and driving significant revenue growth.
Spark’s Take on BON Stock
According to Spark, TipRanks’ AI Analyst, BON is a Neutral.
Bon Natural Life faces significant challenges, with declining financial performance and weak technical indicators. Despite a low P/E ratio indicating possible undervaluation, the lack of dividend yield and negative cash flows highlight operational struggles. The stock’s overall outlook is cautious, emphasizing the need for improvement in revenue and cash flow generation.
To see Spark’s full report on BON stock, click here.
More about Bon Natural Life
Bon Natural Life Limited (BON) is a Cayman Islands company operating in the natural, health, and personal care industries. The company is a leading bio-ingredient solution provider, focusing on natural health products and personal care solutions.
Average Trading Volume: 2,039,883
Technical Sentiment Signal: Sell
Current Market Cap: $3.28M
For detailed information about BON stock, go to TipRanks’ Stock Analysis page.